Could a Jean Coutu Group PJC Inc. & Metro, Inc. Merger Be on the Horizon?

A few reasons why a Jean Coutu Group PJC Inc. (TSX:PJC.A) and Metro, Inc. (TSX:MRU) merger may or may not materialize.

| More on:
The Motley Fool

With increasing difficulty in the grocery retail space and unfavourable, changing dynamics in the pharmacy business in Quebec, come rumours that two Quebec-based businesses — Jean Coutu Group PJC Inc. (TSX:PJC.A) and Metro, Inc. (TSX:MRU) — could potentially merge as a market share move to take on larger rivals such as Loblaw Companies Ltd. (TSX:L).

Among the catalysts which have been touted as potential drivers of such a deal are the successful integration of other large Canadian pharmacy chains with grocery retailers, most notably, the Shoppers Drug Mart integration with Canada’s largest retailer Loblaw in 2013.

In the race for Canadian market share, pharmacy chains are often looked to as complementary businesses for grocery retailers, and the integration between two firms such as Jean Coutu and Metro would make sense from that standpoint.

Another major consideration that has been put out there as a reason why a potential friendly merger between these two firms may materialize is that both Metro and Jean Coutu are based in Quebec and have primarily served the Quebec market since inception.

Combining two Iconic Quebecois companies would prove to be a much easier exercise than a merger with firms operating primarily outside Quebec for obvious reasons.

Potential deal killers of such a merger remain, and one major one that has been pointed to is the fact that Jean Coutu’s founder, (you guessed it) Jean Coutu, is 90 years old and is unlikely to give up control in an empire which has been built over decades; after all, the company, like many other Canadian publicly traded firms, has a dual-share voting structure in which the Coutu family still owns a majority stake in the voting rights of the Coutu chain.

If Mr. Coutu doesn’t want a partnership, no partnership will be had. Good or bad, this is something that is simply out of everyone’s control.

Another major consideration is that it may simply not be the right time to merge, given the recent dip in Jean Coutu’s share price. While shares have rebounded approximately 5% from a dip experienced earlier this month, Jean Coutu’s share price remains more than 12% below its 52-week high, making a deal much less attractive for Jean Coutu at current levels.

Bottom line

Jean Coutu’s pharmacy business took a blow this past week with the announcement that the Quebec government would be cutting its generic drug budget by about 35%.

Jean Coutu’s generic drug business, Pro Doc, is likely to be seriously hurt by these regulations, with brand-name drugs likely to pick up much of the slack left over.

I would wait to see how things shape up before making any sort of moves on either company, given the level of uncertainty that remains in the Canadian pharmacy/grocery space currently.

Stay Foolish, my friends.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any stocks mentioned.

More on Investing

Stock analysts were once excited about construction company Aecon as an investment.

Bull or Bear: Why Analysts Changed Their Tune on Aecon Stock

Analysts had been champing at the bit for the construction company, but the tides have turned.

Read more »

Specialty Brands faces higher raw materials costs.
Dividend Stocks

What’s Next for Premium Brands Stock?

Shares of the specialty food production and distribution company have fallen about 25% since last October.

Read more »

Double exposure of a businessman and stairs - Business Success Concept
Dividend Stocks

2 Interesting Buys in Any Market

Here are two intriguing buys in any market climate that offer defensive appeal as well as growth and income earning…

Read more »

Bank sign on traditional europe building facade
Bank Stocks

Should You Buy Bank Stocks Now?

Canadian bank stocks are getting cheap. Is this the right time to buy?

Read more »

stock data
Stocks for Beginners

2 Reliable Stocks Beginners Can Buy Amid the Market Selloff

As the broader market turmoil continues, new investors can buy these two reliable dividend stocks to get good returns on…

Read more »

Biotech stocks can be good yet risky investments.

Is Bellus Health Stock Still a Buy After 30% Earnings Jump?

The biotech continues to make progress on obtaining FDA approval for its chronic-cough therapy.

Read more »

Dividend Stocks

TFSA Investors: 3 TSX Stocks for Tax-Free Passive Income

These Canadian corporations have strong visibility over future earnings and dividend payouts.

Read more »

Piggy bank next to a financial report

Do You Have Cash Sitting in Your TFSA? Now Is a Great Time to Buy Stocks

If you have cash in your TFSA that you're looking to invest, now is a great time to buy high-quality…

Read more »